Literature DB >> 30919578

Faecal microbiota from patients with cirrhosis has a low capacity to ferment non-digestible carbohydrates into short-chain fatty acids.

Mingliang Jin1,2,3, Sylvia Kalainy4, Nami Baskota1, Diana Chiang5, Edward C Deehan1, Chelsea McDougall4, Puneeta Tandon4, Inés Martínez1, Carlos Cervera5,6, Jens Walter1,7, Juan G Abraldes4.   

Abstract

BACKGROUND AND AIMS: Cirrhosis is associated with dysbiosis, but its functional consequences are still largely unknown. Short-chain fatty acids (SCFAs) account for physiological interactions between the gut microbiota and host. Our aim was to assess the impact of cirrhotic dysbiosis on the production of SCFAs.
METHODS: Seventeen patients with cirrhosis and 17 controls were selected. Microbiota composition in faecal samples was assessed by next-generation 16S rRNA gene sequencing. SCFAs were measured with GC-MS in faecal samples and after in vitro batch fermentations using arabinoxylan, resistant starch, pectin, and lactulose as substrates.
RESULTS: Among the 17 cirrhotic patients (mean age 58, eight males), six, nine and two were, respectively, Child-Pugh class A, B and C. Eleven patients were on oral antibiotics, 11 on lactulose and 13 on proton pump inhibitors. Cirrhotic patients showed marked differences in the composition and diversity of gut microbiome when compared to controls, that were more pronounced with increased severity. Stool samples from cirrhotic patients showed lower SCFAs content and reduced capacity to produce SCFAs in batch fermentations, with butyrate production being the most abnormal. These functional aberrancies were more pronounced with greater liver disease severity. Abundance of Ruminococcus faecis (in family Ruminococcaceae), Faecalicatena fissicatena and Fusicatenibacter saccharivorans (in family Lachnospiraceae) was positively correlated with the SCFAs production.
CONCLUSION: Cirrhotic dysbiosis is associated with a decreased capacity to ferment non-digestible carbohydrates into SCFAs, especially into butyrate. These functional abnormalities are more pronounced as disease progresses. These results might inform the design of gut-targeted therapies for cirrhosis.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  cirrhosis; microbiota; short-chain fatty acids

Year:  2019        PMID: 30919578     DOI: 10.1111/liv.14106

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  27 in total

Review 1.  Interplay of Liver Disease and Gut Microbiota in the Development of Colorectal Neoplasia.

Authors:  Michael W Gleeson
Journal:  Curr Treat Options Gastroenterol       Date:  2019-09

Review 2.  Promises of microbiome-based therapies.

Authors:  Jasmohan S Bajaj; Siew C Ng; Bernd Schnabl
Journal:  J Hepatol       Date:  2022-06       Impact factor: 30.083

3.  A Class IIb Bacteriocin Plantaricin NC8 Modulates Gut Microbiota of Different Enterotypes in vitro.

Authors:  Jiaqian Pu; Shuting Hang; Manman Liu; Ziqi Chen; Jiayi Xiong; Yongquan Li; Hongchen Wu; Xiaodan Zhao; Shuxun Liu; Qing Gu; Ping Li
Journal:  Front Nutr       Date:  2022-06-30

4.  Escherichia/Shigella, SCFAs, and Metabolic Pathways-The Triad That Orchestrates Intestinal Dysbiosis in Patients with Decompensated Alcoholic Cirrhosis from Western Mexico.

Authors:  Tonatiuh Abimael Baltazar-Díaz; Luz Alicia González-Hernández; Juan Manuel Aldana-Ledesma; Marcela Peña-Rodríguez; Alejandra Natali Vega-Magaña; Adelaida Sara Minia Zepeda-Morales; Rocío Ivette López-Roa; Susana Del Toro-Arreola; Erika Martínez-López; Adriana María Salazar-Montes; Miriam Ruth Bueno-Topete
Journal:  Microorganisms       Date:  2022-06-16

5.  Gut dysbiosis and body composition in cirrhosis.

Authors:  Roman Maslennikov; Vladimir Ivashkin; Aliya Alieva; Elena Poluektova; Anna Kudryavtseva; George Krasnov; Maria Zharkova; Yuri Zharikov
Journal:  World J Hepatol       Date:  2022-06-27

6.  Influence of Maternal Inulin-Type Prebiotic Intervention on Glucose Metabolism and Gut Microbiota in the Offspring of C57BL Mice.

Authors:  Qian Zhang; Xinhua Xiao; Jia Zheng; Ming Li; Miao Yu; Fan Ping; Tong Wang; Xiaojing Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2019-10-01       Impact factor: 5.555

7.  Skin Exposure to Narrow Band Ultraviolet (UVB) Light Modulates the Human Intestinal Microbiome.

Authors:  Else S Bosman; Arianne Y Albert; Harvey Lui; Jan P Dutz; Bruce A Vallance
Journal:  Front Microbiol       Date:  2019-10-24       Impact factor: 5.640

8.  Sex is associated with differences in gut microbial composition and function in hepatic encephalopathy.

Authors:  Krishnakant Saboo; Amirhossein Shamsaddini; Mihir V Iyer; Chang Hu; Andrew Fagan; Edith A Gavis; Melanie B White; Michael Fuchs; Douglas M Heuman; Masoumeh Sikaroodi; Ravishankar K Iyer; Patrick M Gillevet; Jasmohan S Bajaj
Journal:  J Hepatol       Date:  2020-07-15       Impact factor: 25.083

Review 9.  Role of the Gut Microbiota in Regulating Non-alcoholic Fatty Liver Disease in Children and Adolescents.

Authors:  Daisuke Tokuhara
Journal:  Front Nutr       Date:  2021-06-25

10.  Liver cirrhosis contributes to the disorder of gut microbiota in patients with hepatocellular carcinoma.

Authors:  Ruipeng Zheng; Guoqiang Wang; Zhiqiang Pang; Nan Ran; Yinuo Gu; Xuewa Guan; Yuze Yuan; Xu Zuo; He Pan; Jingtong Zheng; Fang Wang
Journal:  Cancer Med       Date:  2020-04-12       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.